Atom | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

Funder: National Institutes of Health

Funding Amounts: Up to $499,000 direct costs per year; total direct costs not to exceed $750,000 over up to 3 years (R61/R33 phases combined).

Summary: Supports development and validation of assays and screening to identify potential therapeutic agents for neurological or neuromuscular disorders; clinical trials are not allowed.

Key Information: R61/R33 phased award; clear, quantitative go/no-go milestones are required for transition; both phases must be planned and non-overlapping.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

Sign in to see full grant listing